Details for Patent: 9,724,342

Which drugs does patent 9,724,342 protect, and when does it expire?

Patent 9,724,342 protects CABOMETYX and is included in one NDA.

This patent has forty-seven patent family members in twenty-two countries.

Summary for Patent: 9,724,342

Title:	C-met modulator pharmaceutical compositions
Abstract:	Pharmaceutical compositions and unit dosage forms comprising Compound I are disclosed.
Inventor(s):	Jo Ann Wilson, Khalid Shah
Assignee:	Exelixis Inc
Application Number:	US13/810,537
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,724,342
Patent Claim Types: see list of patent claims	Composition; Dosage form;

Drugs Protected by US Patent 9,724,342

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-001	Apr 25, 2016		RX	Yes	No			Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-002	Apr 25, 2016		RX	Yes	No			Y
Exelixis Inc	CABOMETYX	cabozantinib s-malate	TABLET;ORAL	208692-003	Apr 25, 2016		RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 9,724,342

PCT Information
PCT Filed	July 18, 2011	PCT Application Number:	PCT/US2011/044378
PCT Publication Date:	January 19, 2012	PCT Publication Number:	WO2012/009722

International Family Members for US Patent 9,724,342

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	082252
Argentina	122724
Australia	2011278950
Australia	2016247044